Altered Th17/Treg ratio as a possible mechanism in pathogenesis of idiopathic membranous nephropathy

Idiopathic membranous nephropathy (IMN) as a single organ autoimmune disease is a main cause of nephrotic syndrome in adults which is determined through autoantibodies to podocytes proteins. Th17/regulatory T (Treg) balance has emerged as a prominent factor in the regulation of autoimmunity. In this study, we evaluated the balance of Th17 and Treg cells, expression level of related master transcription factors, cytokines and microRNAs in mononuclear cells of peripheral blood of 30 patients with IMN and 30 healthy individuals before treatment. No significant variation was observed in Th17 cell frequency, retinoic acid receptor-related orphan nuclear receptor γt (RORɣt), signal transducer and Activator of transcription 3(STAT3), IL-17, and IL-23, while IL-21, IL-4, and IL-10 had significant increase in mRNA expression and protein level of peripheral blood mononuclear cells in IMN cases. Reduction in the percentage of Treg cells was also accompanied with significantly decreased expression of Forkhead box P3(FOXP3) and Transforming growth factor beta(TGF-β) in IMN patients compared to the control group. Our study revealed that Th17 cells themselves might not be engaged in the pathogenesis of newly diagnosed patients with IMN; however, decreased T reg cells and increased ratio of Th17/Treg lymphocytes might display a role in the pathogenesis of IMN before treatment.

Effect of bioavailability on the fate of hydrophobic organic compounds and metal in treatment of young landfill leachate by membrane bioreactor

Complex dissolved organic matter (DOM) present in landfill leachate provides reliable media for adsorption of highly hydrophobic contaminants, such as Di 2-ethyl hexyl phthalate (DEHP). In this research, the feasibility of submerged membrane bioreactor (SMBR) for treatment of landfill leachate (LFL) was determined. Later, the operating conditions were optimized for removal of DEHP, COD, NH4(+) and PO4(3-), and finally the effect of bioavailability was examined by introduction of different concentrations of humic acid into the influent. The result revealed that presence of complex agglomerated organic compounds increased the removal efficiency of DEHP and COD, even though DEHP biodegradation rate in sludge dramatically decreased (from 58.8% to 12.8%). MBR retention of different metals in the absence and in the presence of recalcitrant DOM was also studied. Like DEHP, ternary interaction between metals, DOM, and sludge play a pivotal role in their removal efficiency and their concentration in sludge.

Occurrence, fate and effects of Di (2-ethylhexyl) Phthalate in wastewater treatment plants: a review

Phthalates, such as Di (2-ethylhexyl) Phthalate (DEHP) are compounds extensively used as plasticizer for long time around the world. Due to the extensive usage, DEHP is found in many surface waters (0.013-18.5 μg/L), wastewaters (0.716-122 μg/L), landfill leachate (88-460 μg/L), sludge (12-1250 mg/kg), soil (2-10 mg/kg). DEHP is persistent in the environment and the toxicity of the byproducts resulting from the degradation of DEHP sometime exacerbates the parent compound toxicity. Water/Wastewater treatment processes might play a key role in delivering safe, reliable supplies of water to households, industry and in safeguarding the quality of water in rivers, lakes and aquifers. This review addresses state of knowledge concerning the worldwide production, occurrence, fate and effects of DEHP in the environment. Moreover, the fate and behavior of DEHP in various treatment processes, including biological, physicochemical and advanced processes are reviewed and comparison (qualitative and quantitative) has been done between the processes. The trends and perspectives for treatment of wastewaters contaminated by DEHP are also analyzed in this review.

The antiparkinsonian efficacy of bromocriptine

The antiparkinsonian activity of bromocriptine, a presumed dopaminergic receptor agonist, was investigated in monkeys with surgically induced tremor and in a group of parkinsonian patients. A single administration of bromocriptine resulted in a dose-dependent relief of tremor in monkeys. Repeated administration enhanced this effect. Only mild abnormal involuntary movements were observed and only after repeated administration. Eleven patients with Parkinson's disease were treated with bromocriptine (mean dose, 26.4 mg a day). Clinically obvious improvement was noted in one or more of the cardinal signs of the disease in six patients (responders). No obvious improvement in any of the cardinal signs was noted in the remaining five patients (nonresponders). Clinically, the responders were older and more severely affected and had been on a higher dose of levodopa. However, they had had the disease for a shorter period. It is suggested that failure to respond to bromocriptine may be related to a decrease in the sensitivity of postsynaptic dopaminergic receptors.